Medicaid Is Tight on Hepatitis C Drug Coverage
April 10, 2017 | Special Report, Hepatitis C, Infection
Direct acting antiviral agents (DAAs) are remarkably effective for hepatitis C virus (HCV) infection, relatively free of adverse effects, the preferred method for treating patients, and very very expensive. The cost of a 12-week course of therapy initially exceeded US$100,000 and now lies in the range of US$60,000 to US$80,000. Perhaps it’s not surprising, then, that private insurance companies and state Medicaid programs balked at providing these drugs to their insured customers.
Index Of Articles
The controversy over expensive new drugs for hepatitis C
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"
Link to research and news articles addressing the high cost of hepatitis C drugs; insurance restrictions - private insurers/Medicaid - and availability of generic versions/India, Egypt and other lower-income countries or through online "buyers clubs"
No comments:
Post a Comment